On May 26, 2020, Dr. Oleh Hornykiewicz died at the age of 93 years. His twin discoveries in the early 1960s of dopamine deficiency in the brains of subjects with Parkinson's disease and the amelioration of patients' symptoms by levodopa therapy represent milestone events in the history of medicine. These breakthroughs enabled much-needed relief for millions of patients suffering from neurological disorders every year and have given rise to the field of dopamine signaling in the regulation of complex behaviors in primates. What did Dr. Hornykiewicz, who was actively engaged in research until shortly before his 91st birthday, wish to pass on to younger scientists? What were his thoughts regarding the elusive cause of Parkinson's disease? How did he wish to be remembered? Here, the authors, one a former student and the other an admired colleague, recall messages conveyed by Dr. Hornykiewicz in public lectures; they also share the content of conversations and letters exchanged with him since 2004, as he began to reflect on his legacy. Through Dr. Hornykiewicz's own words and writings, the picture emerges of an extraordinarily committed scientist, who was exemplary in his professional integrity, who knew how to deploy a gallous sense of humor, who displayed little patience for physicians offering advice, and who kept any sense of pride over his monumental contributions private. When asked at the age of 91 years about the secrets of his long and fulfilled career in neuroscience, he identified himself as "a mad scientist.…I am someone who continuously fantasizes. I am someone who chases fantastical ideas and who keeps on dreaming…", and as a man who was supported by the loving companionship of his wife, Christine. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756664 | PMC |
http://dx.doi.org/10.1002/mds.28316 | DOI Listing |
Brain
September 2017
Human Brain Laboratory, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
See Jellinger (doi:10.1093/awx190) for a scientific commentary on this article. The enzyme monoamine oxidases (B and A subtypes, encoded by MAOB and MAOA, respectively) are drug targets in the treatment of Parkinson's disease.
View Article and Find Full Text PDFEur J Neurosci
January 2017
Centre for Brain Research, Medical University of Vienna, Vienna, Austria.
In the human brain, the claustrum is a small subcortical telencephalic nucleus, situated between the insular cortex and the putamen. A plethora of neuroanatomical studies have shown the existence of dense, widespread, bidirectional and bilateral monosynaptic interconnections between the claustrum and most cortical areas. A rapidly growing body of experimental evidence points to the integrative role of claustrum in complex brain functions, from motor to cognitive.
View Article and Find Full Text PDFNeurology
September 2016
From the Department of Neurology (Y.F., Y.T.), Juntendo Tokyo Koto Geriatric Medical Center, Tokyo; Department of Neurology (Y.F., Y.T.), Juntendo University Graduate School of Medicine, Tokyo, Japan; Human Brain Laboratory (Y.F., J.T., S.J.K.) and Research Imaging Centre (J.T., S.J.K.), Centre for Addiction and Mental Health, Toronto; Movement Disorders Program Saskatchewan (A.H.R.), University of Saskatchewan/Saskatoon Health Region, Canada; Center for Brain Research (O.H.), University of Vienna, Austria; Departments of Psychiatry and Pharmacology (S.J.K.), University of Toronto, Canada.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!